01739nas a2200217   4500000000100000008004100001260001600042653002800058653001100086653001200097653001400109100001500123700001600138700001200154245004700166856008100213300000900294490000800303520119600311022001401507       2004                            d  c2004 Jan 0610aDiagnosis, Differential10aHumans10aleprosy10aPrognosis1 aBoggild AK1 aKeystone JS1 aKain KC00aLeprosy: a primer for Canadian physicians.  uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC305320/pdf/20040106s00048p71.pdf  a71-80 v1703 a<p>Leprosy is a rare but serious infectious disease caused by Mycobacterium leprae. While global prevalence of the disease is decreasing, increasing rates of immigration from countries where leprosy is endemic have led to the recognition of this illness in North America. Classically, leprosy presents as hypopigmented cutaneous macules along with sensory and motor peripheral neuropathies, although the clinical manifestations vary along a disease spectrum. In addition to primary infection, patients may undergo a "reaction," an acute inflammatory response to the mycobacterium, which leads to pain and erythema of skin lesions and dangerous neuritis. Reactions can occur at any time during the course of leprosy, but they tend to be precipitated by treatment. They are a significant cause of impaired quality of life due to marked nerve damage and thus warrant prompt intervention. Although leprosy may have a protracted onset and be difficult to recognize, cure is achievable with appropriate multidrug therapy. Because untreated leprosy can result in permanent, irreversible nerve damage and secondary transmission, early diagnosis and treatment are essential to minimize morbidity.</p>  a0820-3946